{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:14:50Z","timestamp":1786378490389,"version":"build-2736575974"},"reference-count":38,"publisher":"The Endocrine Society","issue":"2","funder":[{"name":"Novo Nordisk A\/S"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Variations in the prevalence and etiology of type 2 diabetes (T2D) across race and ethnicity may affect treatment responses. Semaglutide is a glucagon-like peptide-1 analog approved for once-weekly, subcutaneous treatment of T2D.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To compare semaglutide efficacy and safety in race and ethnicity subgroups across the SUSTAIN trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Post hoc analysis of data from phase 3 randomized SUSTAIN 1\u20135 and 7 (pooled), and SUSTAIN 6 trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>3074 subjects (SUSTAIN 1\u20135 and 7) and 1648 subjects (SUSTAIN 6).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions<\/jats:title>\n                  <jats:p>Semaglutide 0.5 or 1.0 mg, placebo, or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg, insulin glargine 100IU\/ml and dulaglutide 0.75 or 1.5 mg).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>Change in hemoglobin A1C (HbA1c) and body weight from baseline to weeks 30, 40 and 104, and other efficacy and safety endpoints.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>HbA1c was reduced from baseline by 1.0 to 1.5 percentage points and 1.3 to 2.0 percentage points, and body weight was reduced by 2.3 to 4.7 kg and 3.6 to 6.1 kg with semaglutide 0.5 and 1.0 mg, respectively, across race and ethnicity subgroups. Minor changes in blood pressure and lipid profiles were observed. Adverse events (AEs) were reported in similar proportions of subjects across trials. More Asian versus other race subgroups discontinued treatment prematurely due to AEs. The most commonly reported AEs were gastrointestinal disorders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this SUSTAIN trials post hoc analysis, semaglutide was associated with consistent and clinically relevant reductions in HbA1c and body weight in subjects with T2D, with minor variations in efficacy and safety outcomes associated with race or ethnicity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgz072","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T11:00:31Z","timestamp":1574766031000},"page":"543-556","source":"Crossref","is-referenced-by-count":58,"title":["Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6660-0568","authenticated-orcid":false,"given":"Cyrus","family":"DeSouza","sequence":"first","affiliation":[{"name":"University of Nebraska Medical Center, Omaha, NE, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[{"name":"L\u2019Institut du Thorax, Department of Endocrinology, CHU Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Garg","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Diabetes, University of Colorado Denver, Denver, CO, US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna","family":"Lausvig","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Navarria","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Tulane University Health Sciences Center, New Orleans, LA, US"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"key":"2021122114555836600_CIT0001","author":"Centers for Disease Control and Prevention"},{"issue":"3","key":"2021122114555836600_CIT0002","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7326\/0003-4819-125-3-199608010-00011","article-title":"Non-insulin-dependent diabetes mellitus in minorities in the United States","volume":"125","author":"Carter","year":"1996","journal-title":"Ann Intern Med."},{"issue":"1","key":"2021122114555836600_CIT0003","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/ijerph15010078","article-title":"Environmental risk factors for developing type 2 diabetes mellitus: A systematic review","volume":"15","author":"Dendup","year":"2018","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"2021122114555836600_CIT0004","doi-asserted-by":"crossref","first-page":"796","DOI":"10.2337\/dc13-0598","article-title":"Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians","volume":"37","author":"M\u00f8ller","year":"2014","journal-title":"Diabetes Care."},{"issue":"1","key":"2021122114555836600_CIT0005","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4103\/2230-8210.146881","article-title":"Glucagon-like peptide 1 and dysglycemia: conflict in incretin science","volume":"19","author":"Singh","year":"2015","journal-title":"Indian J Endocrinol Metab."},{"issue":"11","key":"2021122114555836600_CIT0006","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1345\/aph.1R041","article-title":"Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis","volume":"46","author":"Park","year":"2012","journal-title":"Ann Pharmacother."},{"issue":"10","key":"2021122114555836600_CIT0007","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/dom.12293","article-title":"Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis","volume":"16","author":"Kim","year":"2014","journal-title":"Diabetes Obes Metab."},{"issue":"5","key":"2021122114555836600_CIT0008","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/jdi.12305","article-title":"Incretin physiology and pathophysiology from an Asian perspective","volume":"6","author":"Cho","year":"2015","journal-title":"J Diabetes Investig."},{"issue":"2","key":"2021122114555836600_CIT0009","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/dom.13082","article-title":"Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes","volume":"20","author":"Seino","year":"2018","journal-title":"Diabetes Obes Metab."},{"issue":"5","key":"2021122114555836600_CIT0010","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/dom.13218","article-title":"Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial","volume":"20","author":"Kaku","year":"2018","journal-title":"Diabetes Obes Metab."},{"issue":"2","key":"2021122114555836600_CIT0011","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/met.2011.0108","article-title":"The triglyceride paradox in people of African descent","volume":"10","author":"Yu","year":"2012","journal-title":"Metab Syndr Relat Disord."},{"issue":"2","key":"2021122114555836600_CIT0012","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.atherosclerosis.2006.12.018","article-title":"Ethnic differences in the ability of triglyceride levels to identify insulin resistance","volume":"196","author":"Sumner","year":"2008","journal-title":"Atherosclerosis."},{"issue":"5","key":"2021122114555836600_CIT0013","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ajcn\/75.5.827","article-title":"Differences in the relation of obesity to serum triacylglycerol and VLDL subclass concentrations between black and white children: the Bogalusa Heart Study","volume":"75","author":"Freedman","year":"2002","journal-title":"Am J Clin Nutr."},{"issue":"18","key":"2021122114555836600_CIT0014","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem."},{"key":"2021122114555836600_CIT0015","author":"US Food and Drug Administration"},{"issue":"4","key":"2021122114555836600_CIT0016","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"2021122114555836600_CIT0017","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"2021122114555836600_CIT0018","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care."},{"issue":"5","key":"2021122114555836600_CIT0019","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"2021122114555836600_CIT0020","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"19","key":"2021122114555836600_CIT0021","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"issue":"4","key":"2021122114555836600_CIT0022","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2021122114555836600_CIT0023"},{"key":"2021122114555836600_CIT0024","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.2337\/dc18-S006","article-title":"6. Glycemic targets: standards of medical care in diabetes\u20142018","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"issue":"5","key":"2021122114555836600_CIT0025","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.2337\/dc12-2480","article-title":"Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society","volume":"36","author":"Seaquist","year":"2013","journal-title":"Diabetes Care."},{"issue":"4","key":"2021122114555836600_CIT0026","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jama.2015.19394","article-title":"Analyzing repeated measurements using mixed models","volume":"315","author":"Detry","year":"2016","journal-title":"JAMA."},{"issue":"1","key":"2021122114555836600_CIT0027","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pst.397","article-title":"Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies","volume":"10","author":"Chuang-Stein","year":"2011","journal-title":"Pharm Stat."},{"key":"2021122114555836600_CIT0028","author":"European Medicines Agency"},{"issue":"20","key":"2021122114555836600_CIT0029","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"9","key":"2021122114555836600_CIT0030","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1111\/dom.13353","article-title":"Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials","volume":"20","author":"Ahr\u00e9n","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"2021122114555836600_CIT0031","first-page":"A293","article-title":"Semaglutide reduces body weight across baseline BMI subgroups across SUSTAIN 1\u20135","volume":"66","author":"Leiter","year":"2017","journal-title":"Diabetes"},{"key":"2021122114555836600_CIT0032","doi-asserted-by":"crossref","first-page":"A287","DOI":"10.2337\/db18-1083-P","article-title":"Semaglutide reduces body weight vs dulaglutide across baseline BMI subgroups in SUSTAIN 7","volume":"67","author":"Viljoen","year":"2018","journal-title":"Diabetes"},{"key":"2021122114555836600_CIT0033","author":"US Department of Health and Human Services Office of Minority Health"},{"issue":"6","key":"2021122114555836600_CIT0034","doi-asserted-by":"crossref","first-page":"589","DOI":"10.4158\/EP-2018-0444","article-title":"Greater combined reductions in HbA1C \u22651.0% and weight \u22655.0% with semaglutide versus comparators in type 2 diabetes","volume":"25","author":"Rodbard","year":"2019","journal-title":"Endocr Pract."},{"issue":"6","key":"2021122114555836600_CIT0035","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/dom.13296","article-title":"Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial","volume":"20","author":"Fr\u00edas","year":"2018","journal-title":"Diabetes Obes Metab."},{"issue":"4","key":"2021122114555836600_CIT0036","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s13300-018-0461-x","article-title":"Efficacy and safety of sitagliptin in hispanic\/latino patients with type 2 diabetes: a pooled analysis from ten randomized, placebo-controlled phase 3 clinical trials","volume":"9","author":"Raji","year":"2018","journal-title":"Diabetes Ther."},{"issue":"6","key":"2021122114555836600_CIT0037","first-page":"e85","article-title":"Heart disease and stroke statistics\u20132006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"113","author":"Thom","year":"2006","journal-title":"Circulation."},{"issue":"6 suppl","key":"2021122114555836600_CIT0038","first-page":"S25","article-title":"Safety of once-weekly glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes","volume":"67","author":"Frias","year":"2018","journal-title":"J Fam Pract."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgz072\/31139330\/dgz072.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/2\/543\/41839451\/jcem_105_2_543.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/2\/543\/41839451\/jcem_105_2_543.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T15:11:41Z","timestamp":1640099501000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/2\/543\/5643670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,26]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,11,26]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgz072","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2]]},"published":{"date-parts":[[2019,11,26]]}}}